Study of a new medicine for bronchiectasis with chronic Pseudomonas infection
Part of Infections, Lungs & breathing clinical trials.
This study tests a new medicine (AZD0292) given through a vein for people with bronchiectasis and a chronic Pseudomonas lung infection. It aims to see if it can reduce flare-ups and improve lung health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older and weigh at least 77 pounds (35 kg).
- You have been diagnosed with bronchiectasis (widened lung airways) confirmed by a CT scan.
- You have had at least 2 moderate or 1 severe bronchiectasis flare-up in the past year that needed antibiotics.
- You have had a positive test for Pseudomonas aeruginosa bacteria in your sputum or airway sample in the last 2 years.
- You are not currently on long-term oxygen therapy, certain antibiotics, or new medications for your lungs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called AZD0292 for people with bronchiectasis who have a long-term Pseudomonas infection. It aims to see if the drug can reduce flare-ups and improve lung health.
This trial tests a new drug called CTX-187 in two groups: healthy volunteers (Parts A and B) and people with chronic lung infection from bronchiectasis (Part C). It helps find the right dose and checks safety.
This trial tests whether a new medication, BI 1291583, can help people with bronchiectasis reduce lung infections and symptoms. You may join if you have had at least one or two lung flare-ups in the past year.
This trial tests two different antibiotic treatments for adults with bronchiectasis who have a new or recent infection with Pseudomonas aeruginosa (PA) bacteria in their airways. The goal is to see which regimen works better to clear the infection early.
This trial tests if a new drug, GSK3862995B, is safe and effective for adults with bronchiectasis. It might help reduce lung infections and improve symptoms.
This trial tests a new drug called AZD6793 for people with moderate to very severe COPD. It aims to see if the drug can help improve breathing and reduce flare-ups.
Hear when a new Bronchiectasis With Pseudomonas Aeruginosa Colonization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.